| Title of the Activity: 2024 State-of-th | e-Art Clinical Sympsoium Fo | rmat: Live, In-Person Date o | f Activity: April 12-14, 2024 | Total Credits: 9.5 |
|---|--|---|---|---|
| Individual's Name | Individual's Role(s) in Activity | Name of Ineligible Company/Companies | Nature of Relationship(s) ROLE | Mitigation of Conflicts of Interest |
| | | | Advisor or Review Panel Member | Door review of planning and |
| | | AURINA | (Terminated, August 2023) | Peer review of planning and |
| | | GlaxoSmithKlein (GSK) | Consultant | content decisions by persons |
| | | L | Advisor or Review Panel Member | without relevant financial |
| Narender Annapureddy, MD, MS Anne Bass, MD | Planner, Faculty (Moderator) Faculty (Speaker) | Novartis None | (Terminated July 2022) None | relationships N/A |
| S. Louis Bridges, MD, PhD | Faculty (Speaker) | None | None | N/A |
| Matthew Bunyard, MD, RhMSUS | Planner, Faculty (Moderator) | None | None | N/A |
| | | | | Peer review of planning and |
| | | | | content decisions by persons |
| | | | | without relevant financial |
| Kevin Byram, ND | Planner, Faculty (Moderator) | Hemoshear Therapeutics | Consultant (Terminated August 2023) | relationships |
| Dawn Pedrotty, MD, PhD | Faculty (Speaker) | None | None | N/A |
| Marcela Ferrada, MD | Faculty (Speaker) | None | None | N/A |
| Carlos Ferreira | Reviewer | None | None | N/A |
| Tracy Frech, MD, MS | Faculty (Speaker) | None | None | N/A |
| | Planner, Faculty (Speaker, | | 1 | |
| Sobia Hassan, MD, RhMSUS, MRCP | Moderator) | None | None | N/A Peer review of planning and |
| | | Bristol-Myers Squibb (BMS) | Advisor or Review Panel Member | content decisions by persons |
| | | | | without relevant financial |
| Chadwiele Jahr NAD | Faculty (Canaling) | Drietal Museus Caville (DNAC) | Consultant | |
| Chadwick Johr, MD | Faculty (Speaker) | Bristol-Myers Squibb (BMS) Chemomab | Consultant Advisor or Review Panel Member | relationships |
| | | GlaxoSmithKlein (GSK) | Consultant | 1 |
| | | Supposition (OSK) | Sonsaltunt | Peer review of planning and |
| | | | | content decisions by persons |
| | | | | without relevant financial |
| Dinesh Khanna, MD, MSc | Faculty (Speaker) | Zuro Bio | Consultant | relationships |
| Lisa Korn, MD, PhD | Planner, Faculty (Moderator) | None | None | N/A |
| Aman Kugasia, MD | Planner, Faculty (Moderator) | None | None | N/A |
| | | | | Peer review of planning and |
| | | | | content decisions by persons |
| | | | | without relevant financial |
| Anne-Marie Malfait, MD, PhD | Faculty (Speaker) | Averitas | Consultant | relationships |
| Eli Miloslavsky, MD | Reviewer | None | None | N/A |
| Deeba Minhas, MD | Faculty (Speaker) | None | None | N/A |
| Javier Munoz, MD | Faculty (Speaker) | Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly | Consultant | Peer review of planning and content decisions by persons without relevant financial relationships |
| Javier Munoz, MD Javier Munoz, MD | Faculty (Speaker) Faculty (Speaker) | Targeted Oncology, OncView, Curio, Physicians' Education Resource, and Seattle Genetics. Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene | Honoraria Research | Peer review of planning and content decisions by persons without relevant financial relationships Peer review of planning and content decisions by persons without relevant financial relationships |
| James O'Dell, MD Allison Sanchez-Claudio | Faculty (Speaker) Reviewer | None None | None None | N/A N/A |
| Benjamin Smith, PA-C, DMSc | Faculty (Speaker) | None | None | N/A |
| Denjamin Smith, FA-C, DIVISC | i acuity (Speaker) | THORE . | Advisor or Review Panel Member | |
| | | Argenyx | (Terminated September 2022) | Peer review of planning and |
| | | CSL Behring | Consultant | content decisions by persons |
| | | EBSCO | Topic Editor (Dynamed) | without relevant financial |
| Jinny Tavee, MD | Faculty (Speaker) | Medlink | Author | relationships |
| | | Avalo Therapeutics | Consultant | Peer review or prairing and |
| | | Merck | Consultant | content decisions by persons |
| | | | Consultant (Terminated December | without relevant financial |
| Sara Tedeschi, MD, MPH | Faculty (Speaker) | Novartis | 2022) | relationships |
| Denisha Wise | Reviewer | None | None | N/A |
| | | Amgen | Consultant | Á |
| | | Bristol-Myers Squibb (BMS) | Consultant | Peer review of planning and |
| | | Bristol-Myers Squibb (BMS) | Grant/Research Support | content decisions by persons |
| | | Chugai | Consultant Consultant | without relevant financial |
| Yusuf Yazici, MD | Faculty (Speaker) | Hemay Soligenix | Consultant | relationships |
| Robert L. Grisson, Professor, IM | Planner | None | None | N/A |
| | . minici | 1 | 1 | 1.3.4 |